TTIP Negotiators Need Many More Nights To Negotiate – And Are Planning Just That

Top negotiators of the European Union and United States today underlined after the 14th round of negotiations for the Transatlantic Trade and Investment Partnership (TTIP) that they are still on track for finalising the deal during the outgoing Obama administration. At the same time, they acknowledged that after three years of negotiations some chapters have never been discussed.

Orphan Drugs Finding Home In Markets: Could Be 20% Of All Sales By 2020

Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.

For UNCTAD Ministerial, NGOs Call For Development Focus, Not Trade Rules Enforcement

Days before a major meeting of the governing body of the United Nations Conference on Trade and Development (UNCTAD), over 100 non-governmental organisations worldwide are calling for the organisation to maintain its development role and not help implement international and regional trade rules.

Gilead’s Use Of Patents For $10B Tax Dodge Could Ignite Move For Policy Change

Gilead is the US company whose use of patents to charge $1000 per pill for a hepatitis C medicine in the United States helped make high drug prices a developed country household issue and fodder for elected officials seeking change. Now the company has come under further fire after being found to have moved some US$10 billion overseas to avoid US taxes - even after having received US taxpayer support for its activities - which it orchestrated by moving its patent rights overseas. A new report detailing the company's tax dodge includes a proposal for a way to clamp down on this type of patent activity.

New Book On Price-Reducing Strategies For Essential Medicines Under IPRs

A new book and website examine the impact of intellectual property rights on access to new essential medicines and call for measures that were used to reduce prices of patented HIV medicines to be applied in the case of essential medicines.

Opposition To Kenyan “Anti-Innovation” ICT Bill Grows

A bill introduced in Kenya’s parliament intended to streamline, govern and regulate the country’s information and communications technology (ICT) sector has been met with opposition from different quarters over fears that it could put ICT technicians out of practice and stifle the country’s innovation capacity if passed into law.

Post-Huawei v ZTE: Are FRAND Negotiations Finally More Balanced In Europe?

BARCELONA, Spain -- The Huawei v ZTE Case C - 170/13, 21 July 2015 prescribed some guidelines for fair, reasonable and non-discriminatory (FRAND) licensing negotiations, for both standard-essential patent holders and users. A recent private-sector panel addressed European FRAND case law and the latest information and communications technology industry policy opinions, in particular concerning royalty assessment rate (end-user or technology), royalty stacking, patent pool approach and injunctions.

How Are Licensors And Licensees Adapting To New Scenarios?

BARCELONA, Spain -- A recent industry conference panel here covered topics of changing intellectual property scenarios perceived from different angles, in particular from operating companies which manufacture products or services and patent assertion entities (PAEs).